Limits...
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.

Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A - Int Clin Psychopharmacol (2015)

Bottom Line: Weight gain of at least 7% from study baseline was observed in 16.0, 25.8, and 15.2% of patients, and weight loss of at least 7% was seen in 18.5, 6.7, and 9.1% of patients treated with lurasidone, risperidone, and quetiapine XR, respectively.A shift from normal/underweight baseline BMI status to overweight/obese at month 12 occurred in 10.2, 27.6, and 15.0% of patients in the lurasidone, risperidone, and quetiapine XR groups, respectively.Conversely, 14.3, 1.7, and 7.7% of patients, respectively, shifted from overweight/obese to normal/underweight.

View Article: PubMed Central - PubMed

Affiliation: aDepartment of Psychiatry, University of California, San Diego, California bSunovion Pharmaceuticals Inc., Fort Lee, New Jersey, USA.

ABSTRACT
The objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia. Post-hoc, observed-case analysis included pooled data from six studies on 40-160 mg/day lurasidone; two studies included active comparators (2-6 mg/day risperidone or 200-800 mg/day quetiapine XR). Overall, 593 patients completed 12 months of treatment (N=471 lurasidone, N = 89 risperidone, N = 33 quetiapine XR). The mean baseline weight was 72.8, 80.8, and 72.4 kg in the lurasidone, risperidone, and quetiapine XR groups, respectively. The mean weight change at month 12 was -0.4 kg with lurasidone, +2.6 kg with risperidone, and +1.2 kg with quetiapine XR. Weight gain of at least 7% from study baseline was observed in 16.0, 25.8, and 15.2% of patients, and weight loss of at least 7% was seen in 18.5, 6.7, and 9.1% of patients treated with lurasidone, risperidone, and quetiapine XR, respectively. A shift from normal/underweight baseline BMI status to overweight/obese at month 12 occurred in 10.2, 27.6, and 15.0% of patients in the lurasidone, risperidone, and quetiapine XR groups, respectively. Conversely, 14.3, 1.7, and 7.7% of patients, respectively, shifted from overweight/obese to normal/underweight. In summary, a low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months.

No MeSH data available.


Related in: MedlinePlus

Proportion of patients with at least 7% increase in weight and at least 7% decrease in weight from baseline after 3, 6, 9, and 12 months of treatment with lurasidone (40–160 mg/day), risperidone (2–6 mg/day), or quetiapine XR (200–800 mg/day). *P<0.0001 versus risperidone.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4593468&req=5

Figure 3: Proportion of patients with at least 7% increase in weight and at least 7% decrease in weight from baseline after 3, 6, 9, and 12 months of treatment with lurasidone (40–160 mg/day), risperidone (2–6 mg/day), or quetiapine XR (200–800 mg/day). *P<0.0001 versus risperidone.

Mentions: The proportion of patients with weight gain of at least 7% was 9.3% at month 3 and 16.0% at month 12 with lurasidone, 22.5% at month 3 and 25.8% at month 12 with risperidone, and 12.1% at month 3 and 15.2% at month 12 with quetiapine XR (Fig. 3). Comparisons at month 12 were not statistically significant among the treatment groups. Weight loss of at least 7% at month 12 was observed in a greater proportion of patients receiving lurasidone (18.5%) compared with risperidone (6.7%, P<0.001) or quetiapine (9.1%, P=NS; Fig. 3). After 12 months of treatment with lurasidone, 10.2% of patients who were in the normal/underweight BMI category at baseline had shifted to overweight/obese compared with 27.6% of risperidone patients and 15.0% of quetiapine XR patients. Conversely, 14.3% of patients taking lurasidone had shifted from overweight/obese at baseline to normal/underweight at month 12, compared with 1.7% of patients taking risperidone and 7.7% of patients taking quetiapine XR.


Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.

Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A - Int Clin Psychopharmacol (2015)

Proportion of patients with at least 7% increase in weight and at least 7% decrease in weight from baseline after 3, 6, 9, and 12 months of treatment with lurasidone (40–160 mg/day), risperidone (2–6 mg/day), or quetiapine XR (200–800 mg/day). *P<0.0001 versus risperidone.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4593468&req=5

Figure 3: Proportion of patients with at least 7% increase in weight and at least 7% decrease in weight from baseline after 3, 6, 9, and 12 months of treatment with lurasidone (40–160 mg/day), risperidone (2–6 mg/day), or quetiapine XR (200–800 mg/day). *P<0.0001 versus risperidone.
Mentions: The proportion of patients with weight gain of at least 7% was 9.3% at month 3 and 16.0% at month 12 with lurasidone, 22.5% at month 3 and 25.8% at month 12 with risperidone, and 12.1% at month 3 and 15.2% at month 12 with quetiapine XR (Fig. 3). Comparisons at month 12 were not statistically significant among the treatment groups. Weight loss of at least 7% at month 12 was observed in a greater proportion of patients receiving lurasidone (18.5%) compared with risperidone (6.7%, P<0.001) or quetiapine (9.1%, P=NS; Fig. 3). After 12 months of treatment with lurasidone, 10.2% of patients who were in the normal/underweight BMI category at baseline had shifted to overweight/obese compared with 27.6% of risperidone patients and 15.0% of quetiapine XR patients. Conversely, 14.3% of patients taking lurasidone had shifted from overweight/obese at baseline to normal/underweight at month 12, compared with 1.7% of patients taking risperidone and 7.7% of patients taking quetiapine XR.

Bottom Line: Weight gain of at least 7% from study baseline was observed in 16.0, 25.8, and 15.2% of patients, and weight loss of at least 7% was seen in 18.5, 6.7, and 9.1% of patients treated with lurasidone, risperidone, and quetiapine XR, respectively.A shift from normal/underweight baseline BMI status to overweight/obese at month 12 occurred in 10.2, 27.6, and 15.0% of patients in the lurasidone, risperidone, and quetiapine XR groups, respectively.Conversely, 14.3, 1.7, and 7.7% of patients, respectively, shifted from overweight/obese to normal/underweight.

View Article: PubMed Central - PubMed

Affiliation: aDepartment of Psychiatry, University of California, San Diego, California bSunovion Pharmaceuticals Inc., Fort Lee, New Jersey, USA.

ABSTRACT
The objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia. Post-hoc, observed-case analysis included pooled data from six studies on 40-160 mg/day lurasidone; two studies included active comparators (2-6 mg/day risperidone or 200-800 mg/day quetiapine XR). Overall, 593 patients completed 12 months of treatment (N=471 lurasidone, N = 89 risperidone, N = 33 quetiapine XR). The mean baseline weight was 72.8, 80.8, and 72.4 kg in the lurasidone, risperidone, and quetiapine XR groups, respectively. The mean weight change at month 12 was -0.4 kg with lurasidone, +2.6 kg with risperidone, and +1.2 kg with quetiapine XR. Weight gain of at least 7% from study baseline was observed in 16.0, 25.8, and 15.2% of patients, and weight loss of at least 7% was seen in 18.5, 6.7, and 9.1% of patients treated with lurasidone, risperidone, and quetiapine XR, respectively. A shift from normal/underweight baseline BMI status to overweight/obese at month 12 occurred in 10.2, 27.6, and 15.0% of patients in the lurasidone, risperidone, and quetiapine XR groups, respectively. Conversely, 14.3, 1.7, and 7.7% of patients, respectively, shifted from overweight/obese to normal/underweight. In summary, a low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months.

No MeSH data available.


Related in: MedlinePlus